LegacyXChange Inc (OTCMKTS:LEGX) Is Today's OTC Focus

LegacyXChange Inc (OTCMKTS:LEGX) is currently developing an online site for the trading of collectibles and memorabilia across numerous product categories. Utilizing unique DNA authentication solutions to enable collectibles and memorabilia to be permanently marked through ink in a pen, LEGX's goal is to provide the ongoing ability to guarantee authenticity of items. All items marked with this technology will be sold as Original, directly from athletes and celebrities. The site will also allow third party collectible items to be listed and sold.The company's mission is to help athletes and celebrities take control of their brand through the endorsement of sales of only genuine merchandise. LegacyXChange provides a unique platform for both athletes and collectors to maximize the value of their collectibles and memorabilia through the assurance of DNA verification. LegacyXChange will also feature third party and non-verified items for sale. The company plans on launching its site in the second quarter of 2016.Last year, LEGX entered into an exclusive two-year technology partnership with CSI Protect, LLC, the licensed distributor of SelectaDNA, a provider of DNA-based anti-counterfeiting technology, exclusively for use in the sports collectibles and memorabilia markets, as well as other business verticals. In exchange for the use of the DNA technology and the development of DNA autograph pens to be used for collectible signings, LegacyXChange will reference the authentication technology as "Powered by SelectaDNA and CSI Protect" in all future national advertising and promotions. LEGX CEO Bill Bollander said:

"SelectaDNA and CSI Protect is the leading home asset marking company, located in over 40 countries, with millions of items marked and countless crimes solved, SelectaDNA and CSI Protect have set the bar very high. Together we will offer our customers the exclusive assurance of credibility never before experienced in the collectibles marketplace. This is a significant game changer, and now we can begin the process of gearing up for launch."

Last month, LEGX and SelectaDNA/CSI Protect announced that the two companies have the ability to embed Synthetic DNA in ink used in a variety of writing instruments, ensuring athletes signatures against counterfeiting and ultimately preventing theft. Buyers of originally created collectibles from athletes on LegacyXChange will be assured of ongoing proof of authenticity through forensic analysis of the DNA. CEO Bill Bollander said:

"By inserting the DNA material in a host of writing instruments, we are now able to have athletes and celebrities sign collectibles with the guarantee that the item can always be properly identified as to the original signor, further, because the DNA is embedded microscopically in the ink used for their signature, thieves are not inclined to even attempt to remove the DNA, as it will only remove the signature decreasing the value of the collectible. SelectaDNA, as the world leader in the home asset marking has been extremely helpful in developing these opportunities, which goes to show their level of commitment and enthusiasm for LegacyXChange."

It's important for investors to understand that sports memorabilia is a $12 billion a year business. Each year, an estimated $500 million is lost due to fraudulent memorabilia. LEGX has the solution to this problem and the company hopes that its ecommerce site becomes the go-to marketplace for sports memorabilia buyers and sellers. Just like Ebay, there is no charge for listing 50 items in any 30-day period.Currently trading with a market cap of just $1 million, LEGX is an exciting story on the OTC markets. LEGX has been picked up by a few penny stock newsletters and with such a small market cap, we expect LEGX to be a microcap runner. We will be updating Insider Financial as soon as we know more. For continuing coverage on LEGX, sign up for our free newsletter today and get our next hot stock pick!Disclosure: We have no position in LEGX and have not been compensated for this article.